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ARTICLE
A selective inhibitor of ceramide synthase 1 reveals
a novel role in fat metabolism
Nigel Turner1, Xin Ying Lim2,3, Hamish D. Toop 4, Brenna Osborne 1, Amanda E. Brandon5, Elysha N. Taylor4,
Corrine E. Fiveash1, Hemna Govindaraju1, Jonathan D. Teo3, Holly P. McEwen3, Timothy A. Couttas3,
Stephen M. Butler4, Abhirup Das1, Greg M. Kowalski 6, Clinton R. Bruce6, Kyle L. Hoehn 7, Thomas Fath1,10,
Carsten Schmitz-Peiffer8, Gregory J. Cooney5, Magdalene K. Montgomery1,
Jonathan C. Morris 4 & Anthony S. Don3,9
Speciﬁc forms of the lipid ceramide, synthesized by the ceramide synthase enzyme family,
are believed to regulate metabolic physiology. Genetic mouse models have established C16
ceramide as a driver of insulin resistance in liver and adipose tissue. C18 ceramide, syn-
thesized by ceramide synthase 1 (CerS1), is abundant in skeletal muscle and suggested to
promote insulin resistance in humans. We herein describe the ﬁrst isoform-speciﬁc ceramide
synthase inhibitor, P053, which inhibits CerS1 with nanomolar potency. Lipidomic proﬁling
shows that P053 is highly selective for CerS1. Daily P053 administration to mice fed a high-
fat diet (HFD) increases fatty acid oxidation in skeletal muscle and impedes increases in
muscle triglycerides and adiposity, but does not protect against HFD-induced insulin resis-
tance. Our inhibitor therefore allowed us to deﬁne a role for CerS1 as an endogenous inhibitor
of mitochondrial fatty acid oxidation in muscle and regulator of whole-body adiposity.
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Ceramide is the central metabolite of the sphingolipid family,structurally comprised of a sphingoid base—generally 18carbon dihydrosphingosine or sphingosine—with a variable
length fatty acyl side-chain1,2. Ceramides form the lipid backbone
to which a diverse array of headgroup structures are conjugated,
forming sphingomyelin (SM), glucosyl- and galactosylceramide
(HexCer), gangliosides, and globosides2,3. Ceramides are also sig-
nalling molecules that regulate ER stress4, apoptosis5, insulin
sensitivity1,6, and other physiological functions. At the molecular
level, ceramides inﬂuence membrane ﬂuidity, modulating the
compartmentalisation of cellular signalling processes7,8, and directly
activate speciﬁc protein kinases and phosphatases such as the ubi-
quitous phosphatase PP2A1,3,8. Increased ceramide levels are
heavily implicated in the pathogenesis of insulin resistance9–12 and
neurodegenerative conditions13, whilst decreased levels fuel cancer
cell resistance to therapy3.
Ceramide synthesis in mammals is catalysed by a family of six
ceramide synthases (CerS1-6). These enzymes transfer a variable
length fatty acyl-coenzyme A (CoA) to the amine group of a
sphingoid base1. Studies employing genetic manipulations have
demonstrated that different CerS isoforms exhibit strong preference
for fatty acyl-CoAs with differing carbon chain lengths. CerS1
exclusively uses 18 carbon (C18) fatty acids, forming C18 (d18:1/
18:0) ceramide14–16, whilst CerS2 preferentially forms d18:1/24:0
(C24:0) and d18:1/24:1 (C24:1) ceramides16–18. Thus, ceramide is
not a single lipid entity; rather it is a family of signalling lipids with
important physiological functions, and variation in the ceramide
acyl-chain dramatically inﬂuences the biological properties of these
lipids. Insulin resistance caused by a HFD is alleviated by CerS5 or
CerS6 gene deletion, which prevents C16 ceramide synthesis in liver
and adipose tissue9,10,12. C16 and shorter chain ceramides antag-
onise the insulin receptor—PI3 kinase—Akt signalling pathway and
inhibit fat utilisation as an energy source via β-oxidation1,7,9,19. In
direct contrast, C24 ceramides synthesized by CerS2 protect against
insulin resistance6,9,20. The synthesis of ceramides and other
sphingolipids is regulated by availability of fatty acyl-CoA sub-
strates, particularly palmitoyl-CoA derived from the common
saturated fatty acid palmitate2,21. As such, ceramide synthesis may
act as a direct metabolic sensor of fatty acid availability, feeding
back to regulate metabolic processes.
Another ceramide species implicated in insulin resistance is
C18:011,22,23. CerS1 and its product C18 ceramide are highly
abundant in skeletal muscle (SkM)1,18. Studies comparing obese
insulin resistant and insulin sensitive subjects, exercise interven-
tions in type 2 diabetes, and induction of insulin resistance in
mice, all show an association between muscle C18:0 ceramide and
impairments in insulin action11,22,24. Although a relatively minor
species in plasma, circulating C18 ceramide is also very sig-
niﬁcantly correlated with body mass index25 and visceral fat
mass22. Similarly, C18 ceramide in SkM is positively correlated
with visceral fat, as well as blood pressure22.
Selective inhibition of CerS5, CerS6, and/or CerS1 would
therefore be predicted to produce signiﬁcant beneﬁts for meta-
bolic health, whilst CerS2 inhibition would have detrimental
effects. However, isoform-speciﬁc CerS inhibitors with sufﬁcient
potency, selectivity, and bioavailability for in vivo use have not yet
been developed26,27. This report describes the discovery and
characterisation of the ﬁrst potent, isoform-selective CerS inhi-
bitor, speciﬁcally targeting CerS1. CerS1 inhibition is shown to
promote fatty acid oxidation in SkM and reduce overall adiposity
in mice fed a HFD.
Results
Development of a potent and selective CerS1 inhibitor. To
develop isoform-selective CerS inhibitors, we started with the
multiple sclerosis drug Fingolimod (FTY720, Gilenya), which is
an analogue of the endogenous lipid sphingosine28. Following its
phosphorylation in vivo, Fingolimod is a potent agonist of
sphingosine 1-phosphate receptors, however the non-
phosphorylated pro-drug also exhibits non-selective inhibition
of ceramide synthases as an off-target effect29,30. We recently
established that the non-phosphorylatable, chiral FTY720 analo-
gue AAL(S) and its benzyl tail derivative G024 (Fig. 1a, com-
pound 1), show limited selectivity for CerS1 over other CerS
isoforms27. However, their degree of selectivity for CerS1 is poor
and, importantly, these compounds do not selectively reduce C18
ceramide levels in cultured cells. Using the Topliss tree as a
guide31,32 we examined variations of the benzyl tail of G024,
resulting in the identiﬁcation of (S)-2-amino-4-(4-(3,4-dichlor-
obenzyloxy)phenyl)-2-methylbutan-1-ol (P053, [compound 2])
as a potent and selective CerS1 inhibitor (Fig. 1a, b). The IC50 for
inhibition of CerS1 with P053 was 0.5 μM, an order of magnitude
lower than that of G024 (Table 1). IC50’s for inhibition of CerS2,
CerS4, CerS5, and CerS6 by P053 were all at least one order of
magnitude higher than for CerS1, demonstrating strong selec-
tivity for CerS1 over other CerS isoforms (Fig. 1b and Table 1).
The IC50 for P053 on CerS1 was similar to that of the potent but
non-selective CerS inhibitor Fumonisin B1 (FB1)33, which
inhibited all CerS isoforms with sub-micromolar IC50 (Table 1).
As shown previously by Lahiri et al.29 for CerS2, CerS1 activity as
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Fig. 1 P053 is a selective inhibitor of CerS1. a Structure of G024 [1] and P053 [2]. b Activity of CerS isoforms as a function of P053 concentration (n= 3 for
each concentration, mean ± SEM). c, d CerS1 activity as a function of c dihydrosphingosine or d C18:0-CoA concentration. Calculated Vmax and Khalf values
are below the graphs. Graphs show mean ± SEM (n= 3 for each concentration), and the non-competitive inhibition was conﬁrmed in three independent
experiments for each substrate
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a function of substrate concentration is sigmoidal, particularly for
the C18:0-CoA substrate, indicative of a cooperative binding
model. P053 reduces maximal reaction rate (Vmax) without
notably affecting substrate afﬁnity (Khalf) (Fig. 1c, d), indicating
that it is a non-competitive inhibitor.
In a live-cell ceramide synthase assay34 using cortical neuron
cultures, a two hour pre-treatment with P053 resulted in dose-
dependent inhibition of de novo C18:0 ceramide synthesis from
deuterated dihydrosphingosine (Fig. 2a), conﬁrming that the drug
is cell permeable and inhibits CerS1 activity in living cells. We
next tested the potency and speciﬁcity of our inhibitor in
reducing endogenous ceramides. Most cell lines produce very
little C18 ceramide. HEK293 cells produce more C18 ceramide
than other immortalised cell lines that we tested, and we therefore
quantiﬁed endogenous ceramides in HEK293 cells treated for 24
h with P053. C18:0 ceramide was reduced by 53% with 100 nM
P053 (Fig. 2b, Supplementary Figure 1 and Supplementary Data
File 1). No other forms of ceramide were reduced by P053
treatment, but a minor increase in C24:0 ceramide was observed
(Fig. 2b). In addition to C18 ceramide, the compound selectively
reduced C18 HexCer (Fig. 2c) and SM (Fig. 2d), which are both
derived from C18 ceramide. P053 had no effect on HEK293 cell
viability at or below 1 μM (Fig. 2e).
FTY720 has been reported to inhibit sphingosine kinase 1 in
the low micromolar range35. P053 did not inhibit recombinant
human sphingosine kinase 1 or 2 to any extent at 10 μM, whereas
10 μM FTY720 produced a 60% reduction in sphingosine kinase 1
activity (Supplementary Figure 2).
P053 selectively targets CerS1 in vivo. To investigate the in vivo
efﬁcacy of P053, bioavailability was tested by administering a
single 5 mg/kg dose by oral gavage to mice (Fig. 3a). A maximal
plasma concentration of 20 nM was achieved 4 h after adminis-
tration, with a plasma half-life of 28 h. Expression proﬁling
conﬁrmed previous literature18 and showed that CerS1 is highly
expressed in brain and SkM, with minimal or no expression in
other tissues, including adipose tissue (Fig. 3b). In a pilot study,
7 days administration of P053 at 5 mg/kg/day reduced C18 cer-
amide levels in SkM by 31%, whereas 1 mg/kg/day had no effect.
To fully characterise the effects of the compound on the lipidome,
we administered 5 mg/kg P053 daily for 4–6 weeks to mice fed
either normal chow or a HFD. Of 302 individual lipid species
manually veriﬁed following lipidomic proﬁling of SkM, only 18:1/
18:0 and 18:2/18:0 ceramide were signiﬁcantly reduced at P
< 0.01, after adjusting for multiple comparisons (Fig. 3c–e, and
Table 1 IC50 for inhibition of ceramide synthases by P053
hCerS1 mCerS1 hCerS2 mCerS2 hCerS4 mCerS5 hCerS6
P053 [2] 0.54 ± 0.06 0.46 ± 0.08 28.6 ± 0.15 18.5 ± 0.12 17.2 ± 0.09 7.2 ± 0.10 11.4 ± 0.17
G024 [1] 6.0 ± 0.10 14.5 ± 0.09 18.0 ± 0.12 24.3 ± 0.22 8.5 ± 0.13
FTY720 9.9 ± 0.07 5.6 ± 0.05 19.1 ± 0.10 10.6 ± 0.13 26.0 ± 0.18 15.0 ± 0.07 5.8 ± 0.20
FB1 0.22 ± 0.05 0.15 ± 0.08 0.92 ± 0.06 0.50 ± 0.05 0.29 ± 0.05
Calculated IC50 values (μM) for inhibition of different human (h) or murine (m) CerS isoforms by P053, G024, FTY720, and FB1. IC50 values were calculated using an inhibitor range from 10 nM–100 μM,
as shown in Fig. 1b
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Fig. 2 P053 selectively reduces C18 sphingolipids in cultured cells. a Formation of deuterated ceramide from deuterated (D7) dihydrosphingosine in
cortical neuron cultures pre-treated for 2 h with P053. b–d Endogenous ceramide (b), HexCer (c), and SM (d) levels in HEK293 cells treated for 24 h with
P053 at concentrations indicated on the graphs. Lipid levels are expressed as a percentage of vehicle control levels. Absolute lipid levels are shown in
Supplementary Figure 1, with raw data for these images provided in Supplementary Data File 1. e Percentage of non-viable HEK293 cells determined by
propidium iodide (PI) staining and ﬂow cytometry, following a 72 h treatment with P053. All graphs show combined data from two independent
experiments, each with 3 (a) or 4 (b–d) separate cell treatments, mean ± SEM. Statistical signiﬁcance in (b–d) was determined by t-tests adjusted for
multiple comparisons, comparing all lipids (22 lipids tested in total) at each concentration to the control group; +P < 0.05; #P < 0.01; *P < 0.001
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Supplementary Data File 2). As C18 is the dominant ceramide in
SkM, P053 treatment reduced total ceramide content in this
organ (Fig. 3f; P= 0.73 for effect of diet, P < 0.001 for effect of
P053 by 2-way ANOVA). Very long chain ceramides (C22:0,
C24:0 and C24:1) were signiﬁcantly increased by P053 treatment
in the HFD group (Fig. 3d, e), as was 42:2 SM, which is assumed
to be the 18:1/24:1 (C24:1) form (Fig. 3g). Mean levels of 36:1 SM,
which is derived from C18:0 ceramide, were 13% lower in P053-
treated compared to vehicle-treated mice on both diets (Fig. 3g),
however this effect was not statistically signiﬁcant. HexCer
content was not signiﬁcantly affected by P053 treatment (Sup-
plementary Data File 2). The increase in C24 ceramides was not
associated with increased C24 ceramide synthase activity (Sup-
plementary Figure 3), and may therefore be a consequence of
increased sphingoid base substrate availability due to the reduc-
tion in CerS1 activity. In accordance with this model, sphingosine
levels were increased 22% as a result of CerS1 inhibition with
P053 in mice fed a HFD (Fig. 3h; P= 0.01), and 11% in mice fed a
chow diet (not signiﬁcant). Dihydrosphingosine levels were not
notably affected by P053 treatment (Fig. 3h).
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This untargeted lipidomic data using quadriceps was supported
by targeted analysis of ceramide, SM and HexCer in gastro-
cnemius muscle, which showed a signiﬁcant increase in C18
ceramide content in the HFD compared to the chow control
group, and signiﬁcant reductions in C18 ceramide (i.e., 18:1/18:0),
C18 dihydroceramide (i.e., 18:0/18:0), and 18:2/18:0 ceramide
with P053 treatment (Supplementary Figure 4).
P053 treatment did not affect levels of common phospholipids
from the phosphatidylcholine, phosphatidylethanolamine, phos-
phatidylserine, and phosphatidylinositol families (Supplementary
Data File 2). We noted that the levels of most triacylglycerol
(TAG) species were reduced by more than 50% in SkM of the
HFD+ P053 compared to HFD+ vehicle group (Fig. 3d). Total
SkM TAG content was increased ﬁve-fold in mice on a HFD
compared to a chow diet (Fig. 3i; P= 0.01 for main effect of diet,
P= 0.15 for effect of P053 by two-way ANOVA), and was 60%
lower in the HFD+ P053 group compared to the HFD vehicle
group (P= 0.021). P053 treatment did not affect SkM TAG levels
in mice fed normal chow (Fig. 3i). TAGs are synthesized directly
from diacylglycerol (DG). DG levels were unaffected by P053
treatment (Supplementary Figure 5), suggesting that P053 does
not directly inhibit TAG synthesis from DG.
Of 265 lipids measured in liver, none was signiﬁcantly affected
by P053 treatment in mice fed either chow or HFD (Supplemen-
tary Data File 2), despite the fact that there is substantial uptake
of P053 in the liver (Supplementary Figure 6). There were 40
lipids signiﬁcantly affected by diet (P < 0.01 after adjusting for
multiple comparisons), including C22:0 and C24:1 ceramide
(Fig. 3j), in line with previous results20, and 38:1 SM (Fig. 3k).
Similarly, P053 did not signiﬁcantly impact on levels of C18
ceramide or SM, nor other ceramide or SM species, in adipose
tissue, although there were a number of diet-induced changes
(Fig. 3l, m). The lack of effect of P053 in liver and adipose tissue is
likely a reﬂection of the very low levels of CerS1 in these tissues
(Fig. 3b). Although CerS1 is highly expressed in brain (Fig. 3b),
P053 did not affect C18 ceramide or SM (particularly SM 36:1)
levels in cerebellum (Supplementary Figure 7). This may be a
consequence of three-fold lower levels of the compound in brain
tissue compared to SkM (Supplementary Figure 6).
The action of FTY720 as an immunosuppressant is dependent
on its phosphorylation36,37. AAL(S), from which P053 is derived,
is a non-phosphorylatable FTY720 analogue37. In cultured
HEK293 cells incubated with FTY720, FTY720-phosphate was
clearly detected, whereas the phosphate of P053 was not detected
in either cultured cells or plasma of mice administered the drug,
indicating that like the parent compound AAL(S), P053 is non-
phosphorylatable (Supplementary Figure 8).
CerS1 inhibition prevents fat deposition but not insulin
resistance induced by a HFD. A recent study showed that the C18
ceramide content of SkM is positively correlated with visceral fat
mass in humans22. In vehicle-treated mice in the current study, C18
ceramide levels in SkM were positively correlated, and C24 cer-
amides were inversely correlated, with body fat (Table 2). These
correlations are indicative of a relationship between the ceramide
content of SkM and whole-body adiposity. In agreement with this
hypothesis, P053 treatment signiﬁcantly reduced whole-body fat
mass and the weight of individual white adipose depots in mice fed
a HFD (Fig. 4a–e). Mean fat pad weights were 0.52 g (epididymal)
and 0.27 g (inguinal) higher in mice fed a HFD compared to a chow
diet. This gain in fat mass was almost halved to 0.29 g (epididymal)
and 0.15 g (inguinal) with P053 treatment. This reduced fat mass
was not due to any effect of P053 on food intake (Supplementary
Figure 9). There is a close association between excess adiposity and
insulin resistance38 and as expected HFD-fed mice displayed ele-
vated fasting insulin (Fig. 4f) and became glucose intolerant
(Fig. 4g) due to impaired glucose disposal during the glucose tol-
erance test (Supplementary Figure 10). Hyperinsulinemic/eugly-
cemic clamps revealed that fat-fed animals displayed a lower
glucose infusion rate (indicating whole-body insulin resistance)
(Fig. 4h), impaired peripheral glucose disposal (Fig. 4i) and reduced
insulin-stimulated glucose uptake in SkM (quadriceps and soleus;
Fig. 4j, k). Despite its marked effects on adiposity and SkM cer-
amide, P053 treatment had no impact on any of these measures of
glucose homoeostasis and insulin action (Fig. 4f–k).
CerS1 inhibition primes SkM to oxidise fatty acids. In simple
terms, lipid accumulation in tissues is determined by the balance
between oxidation and storage. Previous studies have reported
that the lipotoxic effects of C16 ceramide are partly due to
inhibition of fatty acid β-oxidation in liver and adipose tissue9,10.
Muscle homogenates from chow and HFD-fed mice treated with
P053 displayed increased oxidation of 14C-palmitate (Fig. 5a),
suggesting that enhanced lipid oxidation may underlie the
reduced lipid accretion in response to P053. To more directly
Fig. 3 CerS1 inhibition selectively reduces C18 ceramide in SkM. a Plasma P053 concentration following a single 5 mg/kg oral dose (n= 5 mice; mean ±
SEM). b CerS1 mRNA expression was determined in a panel of mouse tissues by quantitative PCR (n= 3 mice; horizontal bar shows mean). Levels are
normalised to 18S rRNA. WAT epididymal white adipose tissue, BAT brown adipose tissue. Results for CerS2 are also shown, to demonstrate the presence
of RNA in samples from tissues lacking CerS1 expression. c, d Volcano plots showing P value plotted against fold change for each of 302 lipids in SkM of
P053-treated relative to vehicle-treated mice. c Chow diet, d HFD, n= 18–20 per group. Lipids signiﬁcantly altered in P053 vs vehicle are shown in blue and
labelled by name. e Levels of individual ceramides, f total ceramide, g individual SM species, h dihydrosphingosine (dhSph) and sphingosine (Sph), and
i total TAG, in SkM of mice fed chow or HFD with vehicle or 5 mg/kg P053 for 4–6 weeks (n= 18–20 per group; n= 8–10 per group for dhSph and Sph).
j–m Liver ceramides (j), liver SM species (k), epididymal adipose ceramides (l), and epididymal adipose SM species (m); n= 10 per group. Bar
graphs show mean ± SEM; #P < 0.01; *P < 0.001, as determined by two-tailed t-tests adjusted for multiple comparisons (P values are after adjusting
for multiple comparisons). Box and whisker plots show full data range with 25th—75th percentile boxed, and horizontal bar marking the median. Results in
(f), (h), and (i) were analysed by two-way ANOVA, with Fisher’s exact post-test to compare individual groups (+, P < 0.05; #P < 0.01; *P < 0.001). Raw
data for e, g, j, k, l and m is provided in Supplementary Data File 1
Table 2 Correlations between SkM ceramides and body fat
Body fat (%) WAT weight
Ceramide r P r P
Total 0.010 0.54 0.138 0.40
18:1/16:0 −0.156 0.34 −0.164 0.31
18:1/18:0 0.367 0.020 0.393 0.012
18:1/20:0 −0.197 0.22 −0.030 0.85
18:1/22:0 0.209 0.196 0.267 0.096
18:1/24:0 −0.524 0.0005 −0.464 0.0025
18:1/24:1 −0.5353 0.0004 −0.428 0.0058
Spearman correlation co-efﬁcients (r) and P values are shown. Signiﬁcant associations are in
bold. Body fat % was determined by EchoMRI, whilst WAT weight is the combined weight of
inguinal and epididymal adipose pads. Mice from both chow and HFD groups were used for this
analysis (n= 38 mice). Mice treated with P053 were not included in this analysis, due to the
confounding effect of P053 on muscle ceramides
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differentiate between inhibition of TAG synthesis and enhanced
lipid oxidation, we quantiﬁed TAG synthesis from 14C-palmitate,
as well as production of CO2 and acid soluble metabolites (ASM)
(i.e., β-oxidation intermediates), in soleus muscles from mice
treated for 2 weeks with P053. Incorporation of 14C-palmitate
into TAG during the 1 h incubation was unchanged (Fig. 5b), but
oxidation of 14C-palmitate was signiﬁcantly increased in soleus
muscles from P053-treated mice (Fig. 5c). To assess if this was an
acute effect of the compound, isolated soleus muscles were treated
in vitro for 1.5 h with P053 before the assay. Palmitate oxidation
was not affected by acute P053 treatment (Fig. 5d), suggesting
that prolonged CerS1 inhibition is required to prime SkM to
partition fatty acids to oxidative pathways over storage.
Fatty acid oxidation occurs in mitochondria and ceramides have
been reported to directly inﬂuence mitochondrial function, as well
as mitochondrial morphology and turnover9,19,39. Assessment of
mitochondrial respiration in permeabilised muscle ﬁbres revealed
that the enhanced lipid oxidation in SkM in response to CerS1
inhibition was likely due to an overall increase in mitochondrial
capacity, as there was a signiﬁcant increase in respiratory activity in
the presence of complex I and IV substrates, and a trend for an
increase in complex II activity (Fig. 5e). Increased respiratory
capacity was associated with signiﬁcant up-regulation of genes
encoding both mitochondrial-encoded (Co-2, Cytb, Atp6) and
nuclear-encoded (Ndufb5, Atp5o, Cycs, Cox5b) respiratory com-
plex subunits (Fig. 6a). Respiratory complexes were also up-
regulated at the protein level in SkM of P053-treated mice (Fig. 6b,
c), accompanied by increased activity of the TCA cycle enzyme
citrate synthase—a commonly used marker of mitochondrial
content—and increased activity of the β-oxidation enzyme βHAD
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(P= 0.06) (Fig. 6d). This effect was speciﬁc to muscle, with no
increase in mitochondrial markers in liver (Fig. 7a–c), where CerS1
and C18:0 ceramide are low, and P053 had no signiﬁcant effect on
lipid levels.
Increased transcription of respiratory complex subunits
suggested that P053 enhances mitochondrial biogenesis. Con-
sistent with this, P053 treatment signiﬁcantly increased protein
expression of Pgc-1α, the master regulator of mitochondrial
biogenesis40 (Fig. 6e) and elevated mitochondrial DNA content
(Fig. 6f; P= 0.06 for main effect of P053 in 2-way ANOVA; P=
0.007 for post-test comparing HFD vehicle to HFD+ P053). The
expression of transcriptional regulators of mitochondrial biogen-
esis Gabp1α (Nuclear respiratory factor 2)41 and Nfe2l2 (nuclear
factor (erythroid-derived 2)-like 2)42 was also signiﬁcantly
increased by P053 treatment (Fig. 6g). AMP-activated protein
kinase (AMPK) is an important regulator of mitochondrial
biogenesis in muscle43 whose activity is inﬂuenced by intracel-
lular ceramide levels44. P053 treatment had no effect on
phosphorylation of AMPK or its downstream substrate acetyl-
CoA carboxylase (ACC) (Supplementary Figure 11), suggesting
that this pathway is not involved in the enhanced mitochondrial
function induced by CerS1 inhibition.
Discussion
There is a strong body of evidence indicating that different forms
of ceramide, synthesized by different CerS isoforms, regulate
distinct physiological processes1,8. However, research on the role
of speciﬁc CerS isoforms is hampered by the absence of isoform-
selective CerS inhibitors. Researchers seeking to pharmacologi-
cally inhibit ceramide synthesis in vivo have generally used
myriocin45–47, which inhibits serine palmitoyltransferase, the rate
limiting initial step in the biosynthesis of all sphingolipids. This
report describes the ﬁrst potent and selective inhibitor of any
CerS isoform, facilitating the discovery of a physiological role for
CerS1 in the regulation of mitochondrial function and fatty acid
metabolism. P053 exhibits strong selectivity for CerS1 over other
CerS isoforms, potently and very speciﬁcally reducing C18 cer-
amide levels in cultured cells and mouse SkM. CerS1 inhibition
with P053 was also successfully dissected from non-speciﬁc pro-
apoptotic properties of sphingoid base analogues27,48,49, as the
compound inhibited C18 ceramide synthesis at concentrations at
least one order of magnitude lower than those required to pro-
mote apoptosis in HEK293 cells. Interestingly, the mode of
inhibition was non-competitive with respect to either the
sphingosine or C18 fatty acyl-CoA substrate, suggesting that P053
may bind an allosteric site, possibly a lipid binding site on the
enzyme. In the absence of structural data for the ceramide syn-
thase family, or sitable homology models, we are unable to fully
characterise the mechanism of inhibition. Both CerS1 and CerS4
activities were assayed using C18:0 fatty acid substrate, indicating
that inhibition by P053 is speciﬁc to the CerS1 isoform and not
the speciﬁc fatty acid substrate used to measure enzyme activity.
Our report provides the ﬁrst pharmacological evidence that
endogenous CerS1 is indeed highly selective for C18 fatty acid
substrates, as treatment of cells or mice with P053 resulted in
selective reduction of C18 ceramide. These ﬁndings support
experiments in which CerS1 has been overexpressed15, silenced50,
or knocked out14. We observed small but statistically signiﬁcant
increases in C24 ceramides in SkM of mice following inhibition of
CerS1. This was not associated with increased C24 ceramide
synthase activity and is therefore most likely a consequence of
increased availability of sphingoid base substrates for CerS2-
catalysed C24 ceramide synthesis in the absence of CerS1 activity.
This is consistent with two distinct genetic mouse models of
CerS1 deﬁciency14,51, and supported by our observation that
sphingosine levels were only modestly increased, and dihydro-
sphingosine levels were not increased, in SkM of P053-treated
mice. C22 and C24 ceramide levels are an order of magnitude
higher than free sphingosine in SkM, so re-routing of sphingoid
base substrates into these ceramides would prevent signiﬁcant
increases in sphingosine upon CerS1 inhibition. In both HEK293
cells and mouse SkM the reduction in C18 forms of SM were
much less prominent than the changes in C18 ceramides. These
ﬁndings indicate that either the turnover rate for SM is slower
than ceramide, or that steady state C18 SM levels are pre-
ferentially maintained at the expense of C18 ceramide.
P053 treatment signiﬁcantly affected ceramide content, parti-
cularly C18 ceramide, in SkM, but not liver or adipose tissue. This
tissue-speciﬁc pattern may simply be a reﬂection of the sub-
stantial differences in CerS1 expression/activity between SkM and
other organs. Although CerS1 is highly speciﬁc for C18 ceramide
synthesis, other CerS isoforms, particularly CerS4 and 5, are
capable of catalysing C18 ceramide synthesis12,16. However, it is
also possible that lower abundance ceramide species may be
primarily obtained from the circulation and not through endo-
genous synthesis in some organs. In support of this notion, short-
term infusion of LDL containing C24:0 ceramides in mice was
shown to alter membrane C24:0 ceramide content in SkM52.
Surprisingly, there was no effect of P053 on ceramide levels in the
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Fig. 5 CerS1 inhibition increases palmitate oxidation and mitochondrial respiratory capacity in SkM. a 14C-palmitate oxidation in SkM homogenates from
mice treated for 6 weeks with P053 or vehicle (n= 10 mice). b 14C-palmitate incorporation into TAG, and c 14C-palmitate oxidation, in isolated soleus
muscles taken from mice treated for two weeks with 5 mg/kg P053 or vehicle control (n= 5 mice). Results show nmoles 14C-palmitate converted
to b TAG or c CO2+acid soluble metabolites. d Palmitate oxidation in soleus muscle strips pre-treated for 1.5 h in vitro with 1 μM P053 or vehicle control
(n= 5 mice). e ADP-stimulated (State 3) respiratory complex activities measured in permeabilised extensor digitorum longus muscle ﬁbres of mice treated
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brain, despite high CerS1 expression levels. This appeared to be
due to low uptake and/or retention of P053 in this organ (Sup-
plementary Figure 6), but could also indicate a lower rate of
sphingolipid turnover in brain compared to SkM. Genetic abla-
tion of CerS1 causes neurodegeneration and cerebellar atrophy
during development14,51, and the lack of an effect of P053 on
brain ceramides indicates that treatment with P053 is unlikely to
cause neuronal atrophy.
Our CerS1 inhibitor empowered us to dissect the role for SkM
C18 ceramide in fat metabolism from its proposed role in insulin
sensitivity. C18 ceramide levels were 20–30% higher in SkM of
mice fed a high fat compared to chow diet. CerS1 inhibition with
P053 signiﬁcantly impeded fat deposition in mice fed a HFD and
reduced the C18 ceramide level in SkM to well below that of
control mice, but did not have any impact on glucose disposal,
nor insulin-stimulated glucose uptake into SkM. Blocking total
sphingolipid synthesis with myriocin has been shown to protect
against insulin resistance and hepatic steatosis in rodents45–47, as
has genetic ablation of Cers5 and CerS6 in liver and adipose
tissue10. It is therefore possible that CerS isoforms that are more
highly expressed in liver and adipose tissue, speciﬁcally CerS2,
CerS5, and CerS6, play a much more signiﬁcant role than CerS1
in regulating glucose homoeostasis and insulin action. This, in-
turn, suggests either that the associations between C18 ceramide
and insulin resistance in humans11,22,23 are correlative, but not
causal; or that C18 ceramide in muscle is a more signiﬁcant
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contributor to insulin resistance in humans exposed to a mixed
diet of fats and simple carbohydrates than to rodents on a deﬁned
HFD.
Our results highlight a new role for CerS1 as a key regulator of
mitochondrial oxidative capacity, with chronic CerS1 inhibition
priming SkM to metabolise fatty acids. Palmitate oxidation was
increased in both isolated muscles and SkM homogenates of mice
treated with P053, but not following acute exposure to the drug.
The enhanced palmitate oxidation following CerS1 inhibition was
associated with higher respiratory capacity, increased mitochon-
drial protein levels, and increased gene expression for respiratory
complex subunits. The dependence of these effects on CerS1 was
evident in the fact that P053 treatment affected mitochondrial
markers in SkM but not liver, where CerS1 levels are very low.
Given the substantial contribution of SkM to whole-body energy
expenditure53, enhanced channeling of fatty acids into oxidative
pathways over storage in muscle over the course of the study
provides a rational explanation for the reduced fat deposition in
P053-treated mice on a HFD. However, to the best of our
knowledge, there are no prior studies demonstrating that speci-
ﬁcally enhancing fat metabolism in SkM reduces adiposity in
mice fed a HFD. In fact, previous studies have shown that
genetically enhancing fatty acid oxidation in SkM, through
deletion of acetyl-CoA carboxylase 2 or muscle-speciﬁc expres-
sion of carnitine palmitoyltransferase-1, did not reduce adipos-
ity54–56. An important point of difference with our study is that
increased fatty acid oxidation was coupled with elevated markers
of mitochondrial content and activity, i.e., CerS1 inhibition
appears to have increased overall mitochondrial capacity and not
just altered fuel selection. The rate of palmitate oxidation in
isolated SkM was directly comparable to its incorporation into
TAG (Fig. 5). Over days to weeks the sustained increase in fatty
acid oxidation with P053 may be sufﬁcient to offset fat deposition
and weight gain. Additional evidence using other approaches to
boost mitochondrial content and fatty acid oxidation is required
to further test this possibility.
The precise mechanism through which chronic CerS1 inhibi-
tion changes mitochondrial content and/or function requires
further investigation. Our ﬁndings of elevated expression of PGC-
1α and other important transcriptional regulators of mitochon-
drial content and function (Gabp1α41 and Nfe2l242) suggest
enhanced mitochondrial biogenesis in response to depletion of
C18 ceramide in muscle. Other studies have shown down-
regulation of genes regulating fatty acid metabolism in the
absence of CerS257, associated with reduced β-oxidation of fatty
acids9. These effects were attributed to elevation of C16 ceramide
in the absence of very long chain ceramide synthesis. Similarly,
loss of CerS2 was shown to reduce respiratory enzyme activities
and increase mitochondrial oxidative stress, effects that were also
attributed to elevated C16 ceramide58. Our data indicates that
C18 ceramide behaves similarly to C16 ceramide in suppressing
respiratory enzyme levels and fatty acid β-oxidation. Another
possible contributor to changes in mitochondrial content/func-
tion in response to P053 treatment is reduced mitophagy, since
exogenous CerS1 expression and a mitochondrial-targeted ana-
logue of C18 ceramide were both shown to promote mitophagy39.
Ceramides have also been shown to induce mitochondrial ﬁssion
in SkM cells, reducing their oxidative capacity19. Thus, another
possibility is that CerS1 inhibition, by lowering the overall cer-
amide content of SkM, boosts respiratory capacity via inhibition
of ﬁssion.
There are several lines of evidence in the literature indicating
that ceramides regulate fat storage. Firstly, genetic ablation of the
Drosophila CerS homologue Schlank results in the absence of fat
pads59. Secondly, the serine palmitoyltransferase inhibitor myr-
iocin reduces adiposity and hepatic steatosis in rodents fed a
HFD45–47. Our ﬁnding that CerS1 inhibition signiﬁcantly
impedes fat deposition is perhaps surprising given that CerS1 is
not expressed to a signiﬁcant extent in adipose tissue or liver.
However, C18 ceramide in SkM was positively correlated with
visceral fat mass, blood pressure, and liver fat in a recent study in
humans23, and we identiﬁed a signiﬁcant positive correlation
between C18 ceramide in SkM and whole body fat mass in mice,
as determined by two different methods: Echo MRI and weight of
dissected fat pads (Table 2). Our experiments with P053 suggest
that this is a causal relationship, as P053 signiﬁcantly reduced
C18 ceramide in SkM without affecting ceramide levels in liver
and adipose tissue. We note that an even stronger inverse cor-
relation of C24 ceramides with adipose tissue weight and % body
fat was observed. The inhibition of CerS1 may therefore reduce
adiposity both directly by reducing C18 ceramide in SkM and
indirectly through the associated increase in C24 ceramide. We
cannot deﬁnitively rule out a direct effect of CerS1 inhibition on
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Fig. 7 CerS1 inhibition does not affect mitochondrial markers in liver.
a Western blots of respiratory complex subunits, b densitometry for
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adipose tissue causing reduced adiposity, however, this seems
unlikely given the absence of CerS1 in this tissue and the fact that
C18 and C24 ceramide levels in adipose tissue were not affected
by our inhibitor.
In summary, we have generated the ﬁrst isoform-selective CerS
inhibitor, speciﬁcally targeting CerS1 with nanomolar potency.
Our results support a model in which CerS1 activity and C18
ceramide in SkM are not requisite for the development of insulin
resistance in mice fed a HFD, but do play a very signiﬁcant role in
storage of dietary fats by acting as a brake on mitochondrial fatty
acid oxidation. Our inhibitor will provide a valuable resource for
researchers seeking to understand the functions of CerS1 in
physiology and pathology, and the marked inﬂuence of P053 on
whole-body and tissue-speciﬁc lipid accumulation further
strengthens the notion that targeting ceramide synthesis may be a
viable therapeutic option for treating obesity.
Methods
Synthesis and chemical characterisation of G024 and P053 (2R,5S)-5-Iso-
propyl-3,6-dimethoxy-2-(4′-benzyloxyphenethyl)-2,5-dihydropyrazine. A
solution of n-butyllithium in hexanes (1.7 M, 6.0 mL, 10.25 mmol) was added
dropwise to a solution of freshly distilled (S)-Schöllkopf’s reagent (1.89 g, 10.26
mmol) in freshly distilled THF (22 mL) at −78 °C (dry ice/acetone). The solution
was stirred at −78 °C for 15 min, where it had turned dark yellow. A solution of 2-
(4′-benzyloxyphenyl)-1-iodoethane60 (3.50 g, 10.35 mmol) in freshly distilled THF
(21 mL) at −78 °C was added dropwise. The solution was stirred for a further
30 min at −78 °C then allowed to slowly warm to −15 °C over 4 h. The reaction
mixture was quenched with saturated aqueous sodium bicarbonate solution and
allowed to warm to room temperature. The THF was removed under reduced
pressure and the residue extracted with dichloromethane (×4). The organic extracts
were combined and dried (Na2SO4). The solvent was removed under reduced
pressure and the crude material was puriﬁed by ﬂash chromatography on silica gel,
eluting with 3% ethyl acetate/n-hexane, to afford the product as a clear colourless
oil (3.84 g, quant). ½α25:0CD =− 6 (0.5, CHCl3); 1H NMR (300 MHz; CDCl3) δ 0.70
(d, J= 6.8 Hz, 3 H), 1.06 (d, J= 6.8 Hz, 3H), 1.92–2.02 (m, 1H), 2.07–2.19 (m, 1H),
2.22–2.32 (m, 1H), 2.48–2.64 (m, 1H), 3.69 (s, 3H), 3.70 (s, 3H), 3.97 (t, J= 3.4 Hz,
1H), 4.02–4.07 (m, 1H), 5.04 (s, 2H), 6.89 (dd, J= 2.1, 4.7 Hz, 2H), 7.10–7.12 (m,
2H), 7.29–7.45 (m, 5H); 13C NMR (75MHz; CDCl3) δ 16.8, 19.2, 30.2, 32.0, 36.2,
52.5, 55.1, 60.9, 70.2, 114.8, 127.6, 128.0, 128.7, 129.5, 134.7, 137.4, 157.1, 163.7,
163.9; IR (NaCl, neat) 1694 cm−1; HRMS (ESI-MS): m/z calcd for C24H31N2O3 [M
+H]+ 395.2334, found 395.2320.
(2S,5S)-5-isopropyl-3,6-dimethoxy-2-(4′-benzyloxyphenethyl)-2-methyl-2,5-
dihydropyrazine. A solution of n-butyllithium in hexanes (1.7 M, 5.8 mL, 9.86
mmol) was added dropwise to a solution of (2R,5S)-5-isopropyl-3,6-dimethoxy-2-
(4′-benzyloxyphenethyl)-2,5-dihydropyrazine (3.33 g, 9.38 mmol) in freshly dis-
tilled THF (47 mL) at −78 °C (dry ice/acetone). The solution was stirred at −78 °C
for 15 min, where it had turned dark yellow. Methyl iodide (1.17 mL, 18.79 mmol)
was added dropwise. The solution was stirred for a further 30 min at −78 °C then
allowed to slowly warm to −15 °C over 4 h. The reaction mixture was quenched
with saturated aqueous sodium bicarbonate solution and allowed to warm to room
temperature. The THF was removed under reduced pressure and the residue
extracted with dichloromethane (×4). The organic extracts were combined and
dried (Na2SO4). The solvent was removed under reduced pressure and the crude
material was puriﬁed by ﬂash chromatography on silica gel, eluting with 2% ethyl
acetate/n-hexane, to afford the product as a clear colourless oil (1.55 g, 45 %), with
all analytical data matching that reported in the literature27. ½α25:0CD =−6 (0.5,
CHCl3); 1H NMR (300 MHz; CDCl3) δ 0.70 (d, J= 6.8 Hz, 3H), 1.12 (d, J= 6.8 Hz,
3H), 1.30 (s, 3H), 1.85 (td, J= 5.1, 7.7 Hz, 1H), 2.08 (td, J= 4.3, 8.6 Hz, 1 H),
2.25 (td, J= 4.3, 8.8 Hz, 1H), 2.34–2.48 (m, 2H), 3.70 (s, 3H), 3.71 (s, 3H), 3.93 (d,
J= 3.3 Hz, 1H), 5.04 (s, 2H), 6.87–6.90 (m, 2H), 7.06–7.09 (m, 2H), 7.29–7.44 (m,
5H); 13C NMR (75MHz; CDCl3) δ 17.1, 19.7, 28.7, 30.7, 30.8, 42.9, 52.4, 58.4, 60.5,
70.2, 114.8, 127.6, 128.0, 128.7, 129.4, 135.2, 137.4, 157.0, 162.1, 165.7; IR (NaCl,
neat) 1694 cm−1; HRMS (ESI-MS): m/z calcd for C25H33N2O3 [M+H]+ 409.2491,
found 409.2490.
Methyl (2S)-2-amino-4-(4′-benzyloxyphenyl)-2-methylbutanoate. A solution
of triﬂuoroacetic acid (15 mL, 0.20 mol) in water (30 mL) was added dropwise to a
solution of (2S,5S)-5-isopropyl-3,6-dimethoxy-2-(4′-benzyloxyphenethyl)-2-
methyl-2,5-dihydropyrazine (1.48 g, 4.01 mmol) in acetonitrile (100 mL). The
solution was stirred at room temperature for 4 h after which the acetonitrile was
removed under reduced pressure. The residue was diluted with water and neu-
tralised with portions of solid sodium bicarbonate, then extracted with dichlor-
omethane (×4). The organic extracts were combined and dried (Na2SO4). The
solvent was removed under reduced pressure and the crude material was puriﬁed
by ﬂash chromatography on silica gel, eluting with ethyl acetate, to afford the
product as a clear colourless oil (0.90 g, 72%), with all analytical data matching that
reported in the literature27. ½α23:5CD =+12 (0.5, CHCl3); 1H NMR (300MHz;
CDCl3) δ 1.37 (s, 3H), 1.80–1.90 (m, 1H), 1.96–2.06 (m, 1H), 2.41–2.51 (m, 1H),
2.55–2.65 (m, 1H), 3.70 (s, 3H), 5.04 (s, 2H), 6.88–6.91 (m, 2H), 7.07–7.10 (m, 2H),
7.31–7.44 (m, 5H); 13C NMR (75MHz; CDCl3) δ 26.6, 29.9, 43.1, 52.3, 57.8, 70.1,
114.9, 127.5, 127.9, 128.6, 129.3, 134.0, 137.2, 157.1, 178.0; IR (NaCl, neat)
1733 cm−1; HRMS (ESI-MS): m/z calcd for C19H24NO3 [M+H]+ 314.1756,
found 314.1754.
(2S)-2-amino-4-(4′-benzyloxyphenyl)-2-methyl-1-butanol (G024). Lithium
aluminium hydride (0.15 g, 3.95 mmol) was added as a solid in one portion to a
solution of methyl (2S)-2-amino-4-(4′-benzyloxyphenyl)-2-methylbutanoate
(0.83 g, 2.64 mmol) in freshly distilled THF (40 mL) at 0 °C. The solution was
stirred at 0 °C for 20 min then the cold bath was removed and the solution stirred
at room temperature for 1 h. The reaction was quenched with saturated aqueous
sodium sulphate solution and the mixture was extracted with ethyl acetate (×4).
The organic extracts were combined and washed with saturated aqueous sodium
bicarbonate solution, water and brine, then dried (Na2SO4). The solvent was
removed under reduced pressure and the crude material was puriﬁed by ﬂash
chromatography on silica gel, eluting with 2% methanol/4% triethylamine/
dichloromethane, to afford the product as a white solid (0.54 g, 72%), with all data
matching that reported in the literature27. ½α25:5CD =−2 (0.5, CHCl3); M.p.:
196.7–197.6 °C; 1H NMR (300MHz; CDCl3) δ 1.13 (s, 3H), 1.61–1.71 (m, 2H),
2.59 (t, J= 8.6 Hz, 2H), 3.34 (dd, J= 7.5, 10.3 Hz, 1H), 5.04 (s, 2H), 6.90 (dd, J=
2.1, 4.6 Hz, 2H), 7.09–7.12 (m, 2H), 7.29–7.45 (m, 5H); 13C NMR (75MHz;
CDCl3) δ 24.6, 29.5, 42.2, 53.1, 70.2, 70.3, 115.0, 127.6, 128.0, 128.7, 129.3, 134.8,
137.3, 157.1; IR (NaCl, neat) 3425 cm−1; HRMS (ESI-MS): m/z calcd for
C16H28NO4 [M+H]+ 286.1807, found 286.1807.
(2S)-t-butyl(1-hydroxy-4-(4′-benzyloxyphenyl)-2-methylbutan-2-yl)carba-
mate. Di-t-butyl dicarbonate (0.42 g, 1.94 mmol) was added as a solid in one
portion to a mixture of (2S)-2-amino-4-(4′-benzyloxyphenyl)-2-methyl-1-butanol
(0.36 g, 1.28 mmol) in saturated aqueous sodium bicarbonate solution (12.8 mL)
and ethyl acetate (12.8 mL). The mixture was heated at 70 °C for 16 h then allowed
to cool to room temperature. The solution was diluted with water and extracted
with ethyl acetate (×3). The organic extracts were combined and washed with
brine, then dried (Na2SO4). The solvent was removed under reduce pressure and
the crude material was puriﬁed by ﬂash chromatography on silica gel, eluting with
30% ethyl acetate/n-hexane, to afford the product as a white solid (0.51 g, quant),
with all analytical data matching that reported in the literature61. ½α25:6CD =+ 2
(0.5, CHCl3); 1H NMR (400MHz; CDCl3) δ 1.22 (s, 3H), 1.44 (s, 9H), 1.80–1.88
(m, 1H), 1.99–2.06 (m, 1H), 2.53 (td, J= 7.7, 12.2 Hz, 1H), 2.63 (td, J= 5.2, 12.0
Hz, 1H), 3.62–3.72 (m, 2H), 4.06 (br s, 1H), 4.62 (s, 1H), 5.04 (s, 2H), 6.89–6.91 (m,
2H), 7.10–7.12 (m, 2H), 7.30–7.44 (m, 5H).
(2S)-t-butyl(1-hydroxy-4-(4′-hydroxyphenyl)-2-methylbutan-2-yl)carbamate.
Palladium on carbon (44 mg, 10 wt. %) was added to a solution of (2S)-t-butyl(1-
hydroxy-4-(4′-benzyloxyphenyl)-2-methylbutan-2-yl)carbamate (0.44 g, 1.15
mmol) in dry methanol (30 mL) at room temperature. A hydrogen balloon was
attached to the ﬂask and the ﬂask was evacuated and purged with hydrogen (×3).
The solution was stirred at room temperature for 18 h. The reaction mixture was
diluted with dichloromethane and ﬁltered through a short pad of Celite, eluting
with dichloromethane. The solvent was removed under reduced pressure to afford
the product as a white solid (0.34 g, quant), with all the analytical data matching
that reported in the literature61. ½α25:6CD =+5 (0.5, CHCl3); 1H NMR (300MHz;
CDCl3) δ 1.21 (s, 3H), 1.44 (s, 9H), 1.79–1.87 (m, 1H), 2.04 (td, J= 5.0, 13.4 Hz,
1H), 2.50 (td, J= 4.9, 13.3 Hz, 1H), 2.59 (td, J= 5.1, 12.5 Hz, 1H), 3.63–3.76 (m,
2H), 4.30 (s, 1H), 4.65 (s, 1H), 5.33 (br s, 1H), 6.75 (dd, J= 2.1, 6.4 Hz, 2H),
7.02–7.04 (m, 2H).
(2S)-2-amino-4-(4′-(3,4-dichlorobenzyloxy)phenyl)-2-methylbutan-1-ol
(P053). 3,4-Dichloro-benzyl bromide (20 mg, 81.3 μmol) was added dropwise to a
suspension of (2S)-t-butyl(1-hydroxy-4-(4′-hydroxyphenyl)-2-methylbutan-2-yl)
carbamate (24 mg, 81.3 μmol) and potassium carbonate (34 mg, 0.25 mmol) in dry
DMF (0.8 mL). The suspension was stirred at room temperature for 15 h. The
solution was diluted with water and extracted with ethyl acetate (×3). The organic
extracts were combined and washed with water and brine, then dried (Na2SO4).
The solvent was removed under reduced pressure and the crude material was
puriﬁed by ﬂash chromatography on silica gel, eluting with 30% ethyl acetate/n-
hexane. After dissolving the puriﬁed material in methanol (0.5 mL), a solution of
2 M methanolic hydrochloric acid (0.12 mL, 0.24 mmol) was added dropwise to it
and the resulting solution was heated at reﬂux for 4 h. After cooling to room
temperature, the solvent was removed under reduced pressure. The residue was
dissolved in chloroform and washed with saturated aqueous sodium bicarbonate
solution (×2) and brine, then dried (Na2SO4). The solvent was removed under
reduced pressure to afford the product as a white solid (16 mg, 57%). ½α25:5CD =−2
(0.5, CHCl3); 1H NMR (300MHz; CDCl3) δ 1.15 (s, 3H), 1.63–1.77 (m, 2H), 1.83
(br s, 3H), 2.60 (t, J= 8.5 Hz, 2H), 3.35 (d, J= 10.8 Hz, 1H), 3.41 (d, J= 10.8 Hz,
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1H), 4.98 (s, 2H), 6.85–6.87 (m, 2H), 7.10–7.13 (m, 2H), 7.24–7.35 (m, 1H), 7.44
(d, J= 8.3 Hz, 1H), 7.53 (d, J= 1.6 Hz, 1H); 13C NMR (75MHz; CDCl3) δ 24.4,
29.5, 53.1, 68.8, 70.2, 77.4, 115.0, 126.7, 129.3, 129.5, 130.7, 135.2, 135.51, 135.54,
137.7, 156.6; IR (NaCl, neat) 3425 cm−1; HRMS (ESI-MS): m/z calcd for
C18H22NO2Cl2 [M+H]+ 354.1027, found 354.1017.
FTY720 and FB1 were purchased from Cayman Chemical Company. For
biochemistry and cell treatments, compounds were prepared as stock solutions at
10 mM in DMSO, then diluted in water or cell culture medium.
Ceramide synthase assays. Ceramide synthase assays were carried out using an
HPLC-based assay with a ﬂuorescent NBD-dihydrosphingosine substrate62. All cell
lines used for these assays were originally sourced from ATCC. The enzyme source
was extracts of HEK293 cells exogenously expressing human CerS1, 2, and 6;
U251 cells expressing human CerS4 (which did not express well in HEK293 cells);
and COS cells expressing murine CerS1, 2, and 5. Human CerS expression plas-
mids (pCMV6 plasmids from Origene) were transfected using FuGene-6 trans-
fection reagent, and cells were harvested 24 h after transfection in 20 mM Hepes
pH 7.4, 10 mM KCl, 1 mM dithiothreitol, 3 mM β-glycerophosphate, and EDTA-
free complete protease inhibitor cocktail (Roche). Cells were sonicated in a Diag-
enode Bioruptor sonicating bath for 5 min, after which cell extracts were cleared by
centrifugation at 800 × g for 10 min. Protein concentration in the supernatant was
assayed using the bicinchoninic acid (BCA) assay, and the supernatant stored at
−80 °C. COS cells were infected with lentiviral constructs expressing murine
CerS1, 2, or 5, then homogenised as described above.
The reaction buffer consisted of 20 mM Hepes pH 7.4, 25 mM KCl, 2 mM
MgCl2, 0.5 mM dithiothreitol, 0.1% fatty acid free BSA, 10 μM NBD-
dihydrosphingosine and 50 μM fatty acid free BSA. C18:0-CoA was used as the
fatty acyl substrate for CerS1 and CerS4; C24:1-CoA for CerS2; and C16:0-CoA for
CerS5 and CerS6. All reactions were run in triplicate. Test inhibitors were added,
after which reactions were started with the addition of 2.5–25 μg lysate protein
(optimised depending on the particular CerS isoform being assayed). Assays were
run for 30 min at 37 °C, and stopped with the addition of 200 μL methanol. The
reaction mixture was transferred to a glass HPLC vial with 300 μL fused glass insert
(Thermo Fisher Scientiﬁc) and NBD-dihydroceramide reaction products were
analysed on a Thermo Scientiﬁc Surveyor HPLC connected to a Shimadzu RF-
10AXL ﬂuorescent detector (set to gain of 3). A 3 × 150 mm Agilent XDB-C8
column (5 μM pore size) was used. Data was acquired over a 12 min
chromatography run using: solvent A, 0.2% formic acid, 2 mM ammonium formate
in water; solvent B, 0.2% formic acid, 1 mM ammonium formate in methanol. The
gradient started at 20:80 A/B, increasing to 5:95 A/B over 2 min, then to 100% B
over 6 min. The gradient was then held at 100% B for 2 min, before re-equilibration
to 20:80 A/B for a further 2 min. Peak areas were integrated using Xcalibur
software (Thermo Fisher Scientiﬁc).
Sphingosine kinase assays. Sphingosine kinase assays were performed using
ﬂuorescent NBD-dihydrosphingosine63,64. Reactions containing 50 mM Hepes pH
7.4, 0.01% BSA, 15 mM MgCl2, 2 mM ATP, 10 μM NBD-dihydrosphingosine, and
10 μM FTY720 or P053, were started with addition of 10 ng recombinant human
sphingosine kinase 1 or 2 (R&D Systems), and run for 30 min at 37 °C. Reactions
were stopped with 100 μL methanol, and 5 μL amounts were resolved on Silica Gel
60 thin layer chromatography (TLC) plates using butanol:acetic acid:water (3:1:1).
The ﬂuorescent NBD-dihydrosphingosine 1-phosphate band was quantiﬁed using
a BioRad ChemiDoc imaging system with excitation by UV light.
Preparation of cortical neurons and quantiﬁcation of D7-labelled ceramides.
Mouse cortical neurons were prepared from E16 pups65 and seeded at 5 × 106 cells/
well in poly-D-lysine coated six-well plates. Two weeks after seeding, neurons were
pre-treated for 2 h with P053, then incubated for a further 1 h with 1 μM deuterated
dihydrosphingosine (D7-dhSph). Lipid extraction and quantiﬁcation of D7-
ceramide using liquid chromatography-tandem mass spectrometry (LC-MS/MS)34
is described below.
Administration of P053 to mice. Male C57BL6/J mice were obtained from the
Animal Resources Centre in Perth (WA, Australia). Mice were housed at 22 ± 1 °C
with a controlled 12:12 h light-dark cycle and had ad libitum access to water and
either chow (8% calories from fat) or HFD (45% calories from fat)66 for 4–6 weeks.
P053 (5 mg/kg) was administered daily by oral gavage, with control animals
receiving vehicle (2% DMSO in drinking water). Treatment was commenced at the
same time as mice were randomised to dietary groups. The experiments were
approved by the UNSW animal care and ethics committee (ACEC 15/48B), and
followed guidelines issued by the National Health and Medical Research Council of
Australia.
Lipid extraction. Lipids were extracted from frozen tissue samples or cells using a
two-phase procedure with methyl-tert-butyl ether (MTBE)/methanol/water
(10:3:2.5, v/v/v)67. Frozen tissue samples (~20 mg) were homogenized in 0.2 mL
methanol containing 0.01% butylated hydroxytoluene (BHT), using a Precellys 24
homogenizer and Cryolys cooling unit (Bertin Technologies) with CK14 (1.4-mm
ceramic) beads. The homogenates were spiked with an internal standard mixture
comprising 5 nmole 19:0/19:0 phosphatidylcholine and 2 nmole each of 17:0/17:0
phosphatidylethanolamine, 17:0/17:0 phosphatidylserine, 17:0/17:0 d5-diacylgly-
cerol, 17:0/17:0 phosphatidylglycerol, 14:0/14:0/14:0/14:0 cardiolipin, 18:1/12:0 SM,
18:1/17:0 ceramide, 18:1/12:0 glucosylceramide, 18:1/12:0 lactosylceramide, 18:1/
12:0 sulfatide (all from Avanti Polar Lipids, USA), and 17:0/17:0/17:0 TAG
(Cayman Chemical, USA), then transferred to 10 mL screw cap glass tubes. The
homogenization tubes containing beads were then washed with another 0.3 mL
methanol, and this wash was combined with the ﬁrst methanol extract, after which
1.7 mL MTBE was added and the samples were sonicated in an ice-cold sonicating
water bath (Thermoline Scientiﬁc, Australia) for 30 min. Phase separation was
induced by addition of 417 µL of mass spectrometry-grade water followed by
vortexing and centrifugation at 1000 × g for 10 min. The upper organic phase was
collected into 5 mL glass tubes. The lower phase was re-extracted by adding 1 mL
MTBE, 300 μL methanol, and 250 μL water. The organic phases were combined in
the 5 mL glass tubes and dried under vacuum in a Savant SC210 SpeedVac
(Thermo Scientiﬁc), then reconstituted in 500 μL methanol and stored at −20 °C
until analysis.
HEK293 cells (106 cells/treatment) were treated for 24 h with P053, then
washed with PBS and scraped into 0.6 mL methanol on ice. Lipids were then
extracted using MTBE/methanol/water as described above67.
P053 quantiﬁcation. Plasma samples (20 μL) were extracted with 200 μL metha-
nol containing 20 pmoles AAL(S)27 as the internal standard. The mixtures were
vortexed, then sonicated in ice water using a Bioruptor (Diagenode) for 2 min at 30
s intervals. Extracts were centrifuged at 1400 rpm for 20 min, 4 °C, to clear debris.
Supernatants were transferred to 5 mL glass tubes. The remaining insoluble
material was re-extracted with 1 mL 80% methanol as above, and the supernatant
combined with the ﬁrst extract. The extracts were evaporated under vacuum
(Savant SC210 SpeedVac, Thermo Scientiﬁc). Dried extracts were reconstituted in
200 μL of 80% methanol/0.2% formic acid and stored at −20 °C. On the day of
analysis, the extracts were vortexed thoroughly and centrifuged at 300 × g for 20
min before transferring 100 μL of the supernatant to glass HPLC vials. To extract
P053 from tissues, MTBE/methanol/water extraction was performed as described
above, with AAL(S) as the internal standard.
LC-MS/MS was performed on a TSQ Quantum Access triple quadrupole
mass spectrometer in positive ion mode, coupled to an Accela UPLC system
(Thermo Scientiﬁc). Extracts (20 μL) were separated on a 2 × 100 mm Eclipse
XDB-C8 column with 1.8 μm particle size (Agilent Technologies), using a 7.5
min binary HPLC gradient: 0 min, 70% B (20% A); 1.5 min, 70% B; 3.5 min, 95%
B; 4 min, 95% B; 4.5 min, 70% B; 7.5 min 70% B. Mobile phase A: 2 mM
ammonium formate/1% formic acid in water; mobile phase B: 1 mM ammonium
formate/1% formic acid in methanol. The ﬂow rate was 0.4 mL min−1, increasing
to 0.5 mL min−1 from 5–7 min, and column oven 30 °C. P053 was quantiﬁed
using an external standard curve covering the range 0.1–1000 nM, with all
concentrations normalised to the 20 pmole AAL(S) internal standard.
Visualisation and quantiﬁcation of peaks was performed using Thermo Fisher’s
XCalibur software v2.2. Precursor/product ion m/z values were as follows: 354.3
and 159.0 for P053; 294.0 and 161.1 for AAL(S); 380.3 and 255.2 for FTY720;
388.2 and 255.2 for FTY720-phosphate.
Lipid quantiﬁcation. Lipidomic proﬁling was performed on a QExactive Plus mass
spectrometer with heated electrospray ionization (HESI) probe and a Dionex
UltiMate 2000 LC pump (Thermo Fisher Scientiﬁc). Extracts were resolved on a
2.1 × 100mm Waters Acquity C18 UPLC column (1.7 µm pore size), using a binary
gradient in which mobile phase A consisted of acetonitrile:water (60:40), 10 mM
ammonium formate, 0.1% formic acid; and mobile phase B was isopropanol:acet-
onitrile (90:10), 10 mM ammonium formate, 0.1% formic acid68. The ﬂow rate was
260 µL/min and column oven 55 °C. Data was acquired in full scan/data-dependent
MS2 mode (full scan resolution 70,000 FWHM, scan range 400–1200m/z). The ten
most abundant ions in each cycle were subjected to MS2 using an isolation window
of 1.4m/z, collision energy 30 eV, resolution 17,500, maximum integration time 110
ms and dynamic exclusion window 10 s. An exclusion list of background ions was
used based on a solvent blank. LipidSearch v4.1.30 software (ThermoFisher Sci-
entiﬁc) was used for chromatogram alignment, peak identiﬁcation and integration.
Each lipid peak was manually veriﬁed for column elution time and characteristic
fragment ions. Data were then exported to an Excel spreadsheet for normalisation of
each lipid to its class-speciﬁc internal standard, and lipid concentrations were cal-
culated relative to the internal standard.
Targeted quantiﬁcation of ceramide, HexCer, and SM species in primary
neurons, HEK293 cells, mouse brain, and gastrocnemius muscle lipid extracts was
performed by LC-MS/MS on a TSQ Access triple quadrupole mass spectrometer
(Thermo Fisher Scientiﬁc)69. Lipids were separated on a 3 × 150 mm Agilent XDB-
C8 column (5 μM pore size) with a 10 min isocratic chromatography run using
methanol containing 0.2% formic acid as the mobile phase. Precursor ions were the
precise [M+H] species for each lipid. The m/z 184.1 product ion was used for SM
species, and the 264.3m/z product ion for ceramide and HexCer species.
Deuterated (D7) ceramides were detected as the corresponding m/z+ 7 ions.
Targeted quantiﬁcation of sphingosine and dihydrosphingosine used the HPLC
column and chromatography conditions as described above for P053. Precursor/
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product ion m/z values were: 300.3 and 264.3 for sphingosine; 302.3 and 266.3 for
dihydrosphingosine.
Body composition. Body composition (lean mass and fat mass) was determined by
EchoMRI-900 Body Composition Analyser (EchoMRI Corporation Pte Ltd, Sin-
gapore) in accordance with the manufacturer’s instructions.
Glucose metabolism and insulin action. Mice were fasted for 6 h, then received
50 mg stable isotope-labeled glucose (6,6-2H glucose, Sigma Aldrich) by oral
gavage. Blood glucose was measured with a glucose meter (Accu-Check, Roche,
NSW, Australia) prior to and at 15, 30, 45, 60 and 90 min following gavage.
Additional blood (~10 μL) was collected from the tail tip prior to and at 15 and
60 min following glucose gavage. These samples were used to perform mass iso-
topologue analysis of plasma glucose via gas chromatography–mass spectrometry
(GC–MS)70. Speciﬁcally, plasma glucose was separated into the labelled glucose
load and the endogenous (liver/kidney-derived) unlabelled glucose to permit dif-
ferentiation of glucose disposal from endogenous glucose production (Supple-
mentary Figure 10). Fasting blood insulin was measured using an Ultrasensitive
Mouse Insulin ELISA Kit (Crystal Chem, Illinois, USA).
Hyperinsulinemic-euglycemic clamps. At 5 weeks of diet/drug treatment, mice
underwent surgery to implant catheters into the left carotid artery and right jugular
vein. Catheters were ﬂushed every 1–2 days with heparinised saline to maintain
patency. Approximately 6–8 days post surgery, and after a ~5 h fast, a
hyperinsulinemic-euglycemic clamp was conducted. Mice were conscious, unrest-
rained and were not handled during the procedure to minimize stress. At −90 min,
a primed (5 μCi) continuous infusion (0.05 μCi/min) of [3,3H]-glucose (Perki-
nElmer) was commenced. Samples were collected at −30, −20, −10 and 0 min for
basal glucose turnover (Rd) determination. At time 0, the rate of [3,3H]-glucose was
increased (0.1 μCi/min) and mice received a primed (24mU/kg)-continuous (6 mU/
kg/min) infusion of insulin (Actrapid, Novo Nordisk, Copenhagen, Denmark) with
euglycemia maintained at ~8 mM during the clamp through variable infusion of
glucose (25% solution). Once blood glucose was stable, four sequential samples were
taken to determine insulin-stimulated glucose turnover. A bolus of 2[14C]deox-
yglucose (10 μCi; PerkinElmer) was then administered and blood sampled at 2, 5,
10, 15, 20 and 30min, prior to collection of muscles for determination of glucose
uptake. Glucose uptake into muscle was determined via the following equation:
Rg′ ¼ 2 14C DGPtissue=AUC2 14C
 
DGplasma
 
 arterial glucose½ 
where 2[14C]DGPtissue is the 2[14C]DGP radioactivity in the muscle (in dpm/g),
AUC 2[14C]DGplasma is the area under the plasma 2[14C]DG disappearance curve
(in dpm/min/ml), and [arterial glucose] is the average blood glucose (in mM).
Animal numbers for clamps were n= 9 Chow vehicle, n= 8 Chow P053, n= 6
HFD vehicle and n= 6 HFD P053.
Palmitate oxidation and incorporation into TAG. Tibialis muscles were homo-
genized in 19 volumes of 250 mM sucrose, 10 mM Tris-HCl and 1 mM EDTA, pH
7.4. 50 µL of tissue homogenate was incubated with 450 µL reaction buffer (111
mM Sucrose, 11.1 mM Tris-HCl, 5.56 mM KH2PO4, 1.11 mM MgCl2, 88.9 mM
KCl, 0.22 mM EDTA, 1.11 mM DTT, 2.22 mM ATP, 0.33% FA-free BSA, 2.22 mM
L-carnitine, 0.056 mM CoA, 0.11 mM malate, 0.2 mM palmitate, 0.5 µCi mL−1 [1-
14C]-palmitate, pH7.4) for 90 min at 30 °C, after which reactions were stopped with
addition of 100 µL of 1M perchloric acid. 14C-labelled CO2 was collected in 100 µL
of 1 M NaOH solution for 2 h. 14C-labelled CO2, as well as 14C-labelled ASM
present in the acidiﬁed supernatant, were quantiﬁed by scintillation counting.
To quantify palmitate oxidation in intact SkM, whole soleus muscles were
dissected tendon to tendon and placed into a vial containing pre-warmed (30 °C)
and pre-gassed (95% O2, 5% CO2) modiﬁed Krebs-Henseleit buffer (4% FA-free
BSA, 5 mM glucose, 0.5 mM palmitate, pH 7.4). After a 30 min pre-incubation,
muscles were transferred into vials containing 0.5 mCi/mL of [1-14C]-palmitate
in modiﬁed Krebs-Henseleit buffer for another 1 h. The reaction was stopped by
removal of the muscles and addition of 1 M perchloric acid to the reaction
mixture. 14C-labelled CO2 was quantiﬁed as described above. The muscles were
blotted dry and snap frozen in liquid nitrogen for subsequent lipid extraction and
TLC. Muscles were homogenized using a Polytron (Kinematica, Littau-Lucerne,
Switzerland) in 1.5 mL 2:1 chloroform-methanol (v/v). The homogenates were
then sonicated in ice water for 15 min, after which 0.3 mL of distilled water was
added, samples were vortexed, and centrifuged at 350 × g for 10 min to induce
phase separation. The upper aqueous phase was used to quantify ASM, and the
lower organic phase was collected and dried under stream of N2, then
reconstituted in hexane and spotted on a Silica Gel 60 F254 TLC plate. The TLC
plate was developed in hexane/diethyl ether/glacial acetic acid (85:15:1), then air
dried. TAG bands were visualised using iodine vapour staining, using an external
standard to mark their position, then scraped into vials and quantiﬁed by liquid
scintillation counting.
Respiratory complex activities in permeabilized muscle ﬁbres. Permeabilized
extensor digitorum longus (EDL) ﬁbres were prepared and mitochondrial function
analyzed according to published protocols with some modiﬁcations71,72. Brieﬂy,
EDL muscles were dissected tendon-to-tendon into ice-cold isolation buffer A
(10mM Ca-EGTA buffer, 20 mM imidazole, 20 mM taurine, 49 mM K-MES, 3 mM
K2HPO4, 9.5 mM MgCl2, 5.7 mM ATP, 15mM phosphocreatine, 1 μM leupeptin,
pH 7.1) and ﬁbres were prepared immediately. Fibre bundles (~3mg wet weight)
were treated with saponin (50 μg/mL) for 20 min at 4 °C and subsequently washed
in cold respiration medium B (0.5 mM EGTA, 3 mM MgCl2.6H2O, 20 mM taurine,
10 mM KH2PO4, 20mM HEPES, 0.1% BSA, 15mM potassium-lactobionate,
110mM mannitol, 0.3 mM dithiothreitol, pH 7.1). Mitochondrial respiratory chain
function was analyzed on a Clark-type electrode (Rank Brothers, UK) in situ, in
respiration medium B at 37 °C, with the sequential addition of glutamate (10mM),
malate (5 mM), ADP (2mM), rotenone (0.5 μM), succinate (10mM), antimycin A
(5 μM), N,N,N′,N′-tetramethyl-p-phenylenediamine dihydrochloride (0.5 mM
TMPD), ascorbate (2 mM), and cytochrome c (10 μM). Fibres were recovered after
polarography and results were expressed as nmoles of O2/min/mg of tissue. Mito-
chondrial membrane integrity was veriﬁed by cytochrome c release test71,72.
Western blotting. Tissues were homogenized in RIPA buffer (100 mM NaCl,
10 mM Tris, pH 7.4, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM
EDTA, 10% Glycerol) containing complete protease inhibitor cocktail (Roche) and
phosphatase inhibitors (3 mM β-glycerophosphate, 1 mM sodium orthovanadate,
5 mM sodium ﬂuoride) by bead-beating in a Precellys 24 at 4 °C. Extracts were
centrifuged at 6500 rpm for 10 min at 4 °C. Supernatant was collected and protein
concentrations determined with the Bicinchoninic acid (BCA) assay (Thermo
Scientiﬁc). Protein lysates (15 μg) were resolved on SDS-PAGE, transferred to
polyvinylidene diﬂuoride (PVDF) membrane, and immunoblotted with antibodies
against Complex I subunit NADH dehydrogenase (#ab110242, Abcam), Complex
II succinate dehydrogenase subunit B (#ab14714, Abcam), Complex III subunit
Core 2 Ubiquinol-cytochrome c reductase (#ab14745, Abcam), Complex IV
Cytochrome c oxidase (#11967S, Cell Signaling Technology), Complex V ATP
synthase α subunit (#ab14748, Abcam), PGC1α (#AB3242, Merck Millipore),
AMPKα (#2532S, Cell Signaling Technology), phospho- AMPKα (Thr172)
(#2535S, Cell Signaling Technology), ACC (#3662S, Cell Signaling Technology),
phospho-ACC (Ser 79, which also detects Ser 212 in ACC2, the predominant ACC
isoform in SkM) (#3661S, Cell Signaling Technology) and pan 14-3-3 (#sc-629,
Santa Cruz Biotechnology). All antibodies were used at a dilution of 1:1000. A
common loading control was included on every gel to account for variation in
relative band intensities between different blots. Antibody-antigen binding was
detected using ECL Reagent (GE Healthcare) and imaged on a Fujiﬁlm Las-4000
CCD camera. Bands were quantiﬁed by densitometry with Fuji ImageQuantTL
software. Full images of blots in Fig. 6 are shown in Supplementary Figure 12.
Enzyme activity assays. Liver and tibialis muscle were homogenized 1:19 (w/v) in
50 mM Tris-HCl, 1 mM EDTA, 0.1% Triton X-100, pH 7.4. The homogenates were
subjected to three freeze-thaw cycles and centrifuged for 10 min at 7000 × g at 4 °C.
Supernatants were used to determine the activity of CS and βHAD66. CS activity of
extracts was measured spectrophotometrically in 100 mM Tris–HCl, pH 8.2, 300
mM acetyl CoA, 1 mM MgCl2, 1 mM EDTA, 0.1 mM 5,5′-dithio-bis (2-nitro-
benzoic acid) (DTNB—ε 13.6 mM/cm at 412 nm) and 500 mM oxaloacetate,
started by the addition of oxaloacetate. βHAD assays were conducted in 50 mM
Imidazole buffer, pH 7.4, 1 mM EDTA, 0.15 mM NADH (ε 6.22 mM/cm at 340
nm) and 0.1 mM acetoacetyl-CoA, started by the addition of acetoacetyl-CoA.
Real-time PCR. PCR (40 cycles) was performed on a LightCycler 480 (Roche)
using SensiFAST SYBR mastermix (Bioline). For quantiﬁcation of CerS1 and CerS2
expression, total RNA was puriﬁed from mouse tissues with TRIzol reagent
(Sigma-Aldrich), followed by DNase treatment (Promega), and reverse transcribed
using random hexamer primers with FirstStrand cDNA synthesis kit (Roche),
according to manufacturer’s instructions. CerS1 and CerS2 gene expression was
determined using a standard curve of Ct against input cDNA, and normalised to
18s RNA. For mitochondrial genes and transcriptional regulators in SkM, total
RNA was prepared with TRIzol, and oligo dT primer was used for reverse tran-
scription. Relative gene expression was determined using the ΔΔCt method, with
36B4 and Rpl13 as the reference genes. Samples with excessively high Ct values (Ct
> 30 for the housekeeping genes) were removed from data analysis (two samples
for Fig. 6a, four samples for Fig. 6g). Gene-speciﬁc primers were as follows:
Target geneForward primer Reverse primer
18s rRNA GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG
Cers1 CCACCACACACATCTTTCGG GGAGCAGGTAAGCGCAGTAG
Cers2 ATGCTCCAGACCTTGTATGACT CTGAGGCTTTGGCATAGACAC
36B4 GGCTCCAAGCAGATGCAGCAG CCTGATAGCCTTGCGCATCATGG
Rpl13 AGGAGGCGAAACAAGTCCAC GGAGACTGGCAAAAGCCTTAAAG
mt-Co2 GCCGACTAAATCAAGCAACA CAATGGGCATAAAGCTATGG
mt-Cytb CATTTATTATCGCGGCCCTA TGTTGGGTTGTTTGATCCTG
mt-Atp6 GACGAACATGAACCCTAAT TACGGCTCCAGCTCATAGT
mt-ND5 ACCATGCTTATCCTCACTTCAG AGTATTTGCGTCTGTTCGTCC
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Table a (continued)
Ndufb5 TTTTCTCACGCGGAGCTTTC ATAAAGAAGGCTTGACGACAAACA
Cox5b GCTGCATCTGTGAAGAGGACAAC CAGCTTGTAATGGGTTCCACAGT
Atp5o AGGCCCTTTGCCAAGCTT TTCTCCTTAGATGCAGCAGAGTACA
Cycs GCAAGCATAAGACTGGACCAAA TTGTTGGCATCTGTGTAAGAGAATC
Nfe2l2 TAGATGACCATGAGTCGCTTGC GCCAAACTTGCTCCATGTCC
Nrf1 GTGCTGATGAAGACTCCCCTT TGCCGTGGAGTTGAGGATGT
Gabpα1 TGCCGTGGAGTTGAGGATGT TCCTGCTCTTTTCTGTAGCCT
Mitochondrial DNA. Total DNA was isolated using standard phenol:chloroform
extraction, followed by RNase H (NEB) treatment. Relative levels of nuclear and
mitochondrial DNA were determined by quantitative PCR on a LightCycler 480
(Roche) using SensiFAST SYBR mastermix (Bioline). Primers for quantiﬁcation of
genomic DNA were: 5′- GGCTGTATTCCCCTCCATCG-3′, and 5′- CCAGTTGG
TAACAATGCCATGT-3′; and mitochondrial DNA: 5′- CCCAGCTACTACCATC
ATTCAAGT-3′, and 5′- GATGGTTTGGGAGATTGGTTGATGT-3′73. Calibration
curves of Ct against input DNA were prepared from a pooled sample of mouse SkM
DNA, and used to calculate the relative abundance of mitochondrial to nuclear
DNA in each sample.
Statistical analyses. HEK293 cell culture experiment: Levels of each lipid in P053-
treated HEK293 cells were normalised to the mean of the vehicle control group, and
each concentration was compared to the control using ANOVA with Dunnett’s post-
test. P values were adjusted for multiple comparisons in GraphPad PRISM.
Lipidomic analysis of mouse tissue samples: Three comparisons were made for
each lipid measured: chow control vs chow+ P053, chow control vs HFD control,
and HFD control vs HFD+ P053. Data were log transformed, then subjected to
two-tailed t-tests adjusted for multiple comparisons using GraphPad PRISM
(Benjamini, Krieger and Yekutieli correction, Q= 1%). A single outlier was
identiﬁed using Grubbs test with high stringency (P < 0.001) and removed from the
quadriceps sphingosine measurements.
Physiological and biochemical measures: Total ceramide, total sphingosine, and
total TAG in SkM, western blotting and gene expression data, and physiological
measures, were assessed by two-way ANOVA with diet as one variable and drug as
the other. P values for the main effect of diet (i.e., chow vs HFD) and drug (i.e.,
vehicle vs P053) are reported. Where post-tests were applied, Fisher’s Least
Signiﬁcant Difference test was used.
Correlations: Spearman analysis was used to assess correlations between SkM
ceramides and adipose tissue mass or % body fat.
Data availability. Lipidomic datasets for SkM and liver are provided in Supple-
mentary Data File 2. Data used for bar graphs is provided in Supplementary Data File
1. Other raw data ﬁles supporting the results and conclusions presented in this ma-
nuscript are available from the corresponding authors upon reasonable request.
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